New York, NY – May 2019 – Yamo Pharmaceuticals presented findings from a pilot study of L1-79, a tyrosine hydroxylase inhibitor, at the INSAR 2018 Annual Meeting. The study, involving adolescent and young adult males with Autism Spectrum Disorder (ASD), demonstrated that L1-79 was well-tolerated and showed trends toward improving core symptoms, including socialization and repetitive behaviors.
Key highlights include:
- Social Motivation (SRS-2): 10.6-point improvement (200 mg dose) vs. 3.8 with placebo.
- Socialization (Vineland-2): 7.6-point improvement vs. 1.5 with placebo.
- Repetitive Behaviors (RBS-R): 18.1-point reduction vs. 12.5 with placebo.
For more details, access the full poster below.
